These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32720093)

  • 1. Glucagon stimulation test to assess growth hormone status in Prader-Willi syndrome.
    Casamitjana L; Giménez-Palop O; Corripio R; Pareja R; Berlanga E; Rigla M; Oliva JC; Caixàs A
    J Endocrinol Invest; 2021 Mar; 44(3):621-629. PubMed ID: 32720093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unaltered ratio of circulating levels of growth hormone/GH isoforms in adults with Prader-Willi syndrome after GHRH plus arginine administration.
    Rigamonti AE; Grugni G; Marazzi N; Bini S; Bidlingmaier M; Sartorio A
    Growth Horm IGF Res; 2015 Aug; 25(4):168-73. PubMed ID: 26059749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GHRH plus arginine and arginine administration evokes the same ratio of GH isoforms levels in young patients with Prader-Willi syndrome.
    Rigamonti AE; Crinò A; Bocchini S; Convertino A; Bidlingmaier M; Haenelt M; Tamini S; Cella SG; Grugni G; Sartorio A
    Growth Horm IGF Res; 2018 Apr; 39():13-18. PubMed ID: 29217318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The GHRH + arginine stimulated pituitary GH secretion in children and adults with Prader-Willi syndrome shows age- and BMI-dependent and genotype-related differences.
    Marostica E; Grugni G; De Nicolao G; Marazzi N; Crinò A; Cappa M; Sartorio A
    Growth Horm IGF Res; 2013 Dec; 23(6):261-6. PubMed ID: 24090687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulated GH levels during the transition phase in Prader-Willi syndrome.
    Grugni G; Marzullo P; Delvecchio M; Iughetti L; Licenziati MR; Osimani S; Ragusa L; Salvatoni A; Sartorio A; Stagi S; Crinò A;
    J Endocrinol Invest; 2021 Jul; 44(7):1465-1474. PubMed ID: 33095904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of growth hormone (GH) deficiency in previously GH-treated young adults with Prader-Willi syndrome.
    Donze SH; Damen L; van Alfen-van der Velden JAEM; Bocca G; Finken MJJ; Hoorweg-Nijman GJG; Jira PE; van Leeuwen M; Hokken-Koelega ACS
    Clin Endocrinol (Oxf); 2019 Jul; 91(1):118-123. PubMed ID: 30973645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of arginine plus growth hormone releasing hormone to evaluate growth hormone (GH) secretory status in children with GH deficiency.
    Keller A; Donaubauer J; Kratzsch J; Pfaeffle R; Hirsch W; Kiess W; Keller E
    J Pediatr Endocrinol Metab; 2007 Dec; 20(12):1307-14. PubMed ID: 18341090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overweight/Obese adults with pituitary disorders require lower peak growth hormone cutoff values on glucagon stimulation testing to avoid overdiagnosis of growth hormone deficiency.
    Dichtel LE; Yuen KC; Bredella MA; Gerweck AV; Russell BM; Riccio AD; Gurel MH; Sluss PM; Biller BM; Miller KK
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4712-9. PubMed ID: 25210883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deconvolution-based assessment of pituitary GH secretion stimulated with GHRH+arginine in Prader-Willi adults and obese controls.
    Grugni G; Marostica E; Crinò A; Marzullo P; De Nicolao G; Sartorio A
    Clin Endocrinol (Oxf); 2013 Aug; 79(2):224-31. PubMed ID: 23301953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impairment of GH responsiveness to combined GH-releasing hormone and arginine administration in adult patients with Prader-Willi syndrome.
    Grugni G; Marzullo P; Ragusa L; Sartorio A; Trifirò G; Liuzzi A; Crinò A;
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):492-9. PubMed ID: 16984242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone secretion among adult patients with Prader-Willi syndrome due to different genetic subtypes.
    Grugni G; Giardino D; Crinò A; Malvestiti F; Ballarati L; Di Giorgio G; Marzullo P
    J Endocrinol Invest; 2011; 34(7):493-7. PubMed ID: 20651469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body fat excess and stimulated growth hormone levels in adult patients with Prader-Willi syndrome.
    Grugni G; Crinò A; Bertocco P; Marzullo P
    Am J Med Genet A; 2009 Feb; 149A(4):726-31. PubMed ID: 19267411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum ghrelin levels in growth hormone-sufficient and growth hormone-deficient patients during growth hormone-releasing hormone plus arginine test.
    Tarantini B; Ciuoli C; Checchi S; Montanaro A; Bonato V; Theodoropoulou A; Pasqui L; Pacini F
    J Endocrinol Invest; 2009 Apr; 32(4):335-7. PubMed ID: 19636202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: UPDATE ON GROWTH HORMONE STIMULATION TESTING AND PROPOSED REVISED CUT-POINT FOR THE GLUCAGON STIMULATION TEST IN THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY.
    Yuen KC; Tritos NA; Samson SL; Hoffman AR; Katznelson L
    Endocr Pract; 2016 Oct; 22(10):1235-1244. PubMed ID: 27409821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypothalamic growth hormone-releasing hormone (GHRH) cell number is increased in human illness, but is not reduced in Prader-Willi syndrome or obesity.
    Goldstone AP; Unmehopa UA; Swaab DF
    Clin Endocrinol (Oxf); 2003 Jun; 58(6):743-55. PubMed ID: 12780752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GH/IGF-I axis in Prader-Willi syndrome: evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology.
    Corrias A; Bellone J; Beccaria L; Bosio L; Trifirò G; Livieri C; Ragusa L; Salvatoni A; Andreo M; Ciampalini P; Tonini G; Crinò A
    J Endocrinol Invest; 2000 Feb; 23(2):84-9. PubMed ID: 10800760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostigmine administration in the Prader-Willi syndrome.
    Grugni G; Guzzaloni G; Moro D; Bettio D; De Medici C; Morabito F
    Clin Endocrinol (Oxf); 1998 Jun; 48(6):769-75. PubMed ID: 9713567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic-pituitary-adrenal axes in adults: results from a prospective randomized multicenter study.
    Hamrahian AH; Yuen KC; Gordon MB; Pulaski-Liebert KJ; Bena J; Biller BM
    Pituitary; 2016 Jun; 19(3):332-41. PubMed ID: 26897383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The GH/IGF-I axis and pituitary function and size in adults with Prader-Willi syndrome.
    van Nieuwpoort IC; Sinnema M; Castelijns JA; Twisk JW; Curfs LM; Drent ML
    Horm Res Paediatr; 2011; 75(6):403-11. PubMed ID: 21273761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similar clinical features among patients with severe adult growth hormone deficiency diagnosed with insulin tolerance test or arginine or glucagon stimulation tests.
    Toogood A; Brabant G; Maiter D; Jonsson B; Feldt-Rasmussen U; Koltowska-Haggstrom M; Rasmussen AK; Buchfelder M; Saller B; Biller BM
    Endocr Pract; 2012; 18(3):325-34. PubMed ID: 22068248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.